Amarin Corp Plc (AMRN)

[homebuilder_watcher]

Note from Aegis Capital this morning

BASF, one of the world's largest chemical companies, has massive bandwidth and its approval as a supplier of Vascepa should remove any potential supply bottleneck issues for Amarin going forward. Since Vascepa is a complex drug to make and Amarin's relationship with BASF is an exclusive one, we believe that this appproval constitutes a substantial step forward for Amarin and not only ensures sufficient supply to meet market demand going forward but also creates a substantial barrier to competitive entry, as very few other companies worldwide can bring the kind of scale that BASF is capable of deploying....Amarin could still elect to accept an acquisition offer, ink a partnership, or continue to market Vascepa independently....We believe that Amarin remains highly likely to receive NCE status for Vascepa. Reiterate Buy and $35 target."